Status:
COMPLETED
Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis
Lead Sponsor:
Bayer
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study assesses clinical and imaging long-term data, after early or delayed interferon-beta-1b treatment in patients with a first demyelinating event suggestive of multiple sclerosis (MS), 11 year...
Detailed Description
As optic coherence tomography (OCT) and magnetic resonance imaging (MRI) studies are essential to standardize the procedures and assessments for all OCT and MRI test centers that may take part in this...
Eligibility Criteria
Inclusion
- Male and female patients with clinical-isolated syndrome or multiple sclerosis who have been treated at least once in BENEFIT Study 304747
Exclusion
- Patients who, according to the investigator's judgment, have medical, psychiatric, or other conditions that compromise the patient's ability to understand the purpose of the study
Key Trial Info
Start Date :
September 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
278 Patients enrolled
Trial Details
Trial ID
NCT01795872
Start Date
September 1 2013
End Date
June 1 2014
Last Update
July 27 2015
Active Locations (77)
Enter a location and click search to find clinical trials sorted by distance.
1
Graz, Styria, Austria, 8036
2
Innsbruck, Austria, 6020
3
Bruxelles - Brussel, Belgium, 1200
4
Ghent, Belgium, 9000